Healthcare
Fractyl Health, Inc. Common Stock(GUTS)
Live Price
Offline$0.858
+0.94% today
1Y Change
-50.69%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $50.00M
- Revenue Growth
- -100.0%
- EPS Growth
- -14.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fractyl Health, Inc. Common Stock (GUTS) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $0.86 and down 50.7% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -14.8%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -14.8%, free cash flow -35.1% with operating margin 0.0% and ROIC -89.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GUTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -14.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +11.8% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +29.2% | +11.3% | -0.3% |
2026 Mar 24, 2026 | +178.9% | +16.3% | +6.5% | +37.4% |
2025 Nov 12, 2025 | -2.9% | -0.9% | +17.7% | +103.5% |
Benchmark Edge
GUTS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GUTS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GUTS Max Drawdown
-83.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GUTS and SPY.
Company Overview
Fractyl Health, Inc. Common Stock
NASDAQ Global Market
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
- Leadership
- Harith Rajagopalan
- IPO Date
- Feb 2, 2024
- Employees
- 107
- Street Address
- 17 Hartwell Avenue
- Mailing
- Lexington, MA, 02421
- Region
- Lexington, MA, US
- Reporting Currency
- USD
- Investor Line
- 781-902-8800
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.1
Growth
- Revenue
- -100.0%
- EPS
- -14.8%
- Free Cash Flow
- -35.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 10146.1%
- ROIC
- -89.5%
Balance Sheet
- Debt/Equity
- 6.52
- Current Ratio
- 4.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.